Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Medicines Company (MDCO) has settled the lawsuit over Angiomax (Bivalirudin) patent litigations with Teva Pharmaceuticals USA.
Subscribe to our email newsletter
The settlement includes a license by MDCO to Teva and its affiliates under which Teva may launch a generic bivalirudin product.
Teva admits that the two patents asserted in the lawsuits are valid and enforceable against, and would be infringed by, Teva’s proposed generic bivalirudin products.
In addition, Teva will also supply bivalirudin active pharmaceutical ingredient (API) to MDCO, whichis believed to provide an additional source of API to support planned growth of product use.
MDCO and Teva will submit the agreements to the US Federal Trade Commission and the US Department of Justice.